A new study found that spending on GLP-1 medications such as Ozempic, Wegovy and Zepbound surged to $5.8 billion in 2022 among U.S. adults without diabetes.
The research, published April 1 in the Annals of Internal Medicine, showed the number of non-diabetic adults using these drugs — which are also prescribed for weight loss — more than tripled from 2018 to 2022, rising from 0.1% to 0.4% of the U.S. population, or an estimated 854,000 people.
Despite the high cost, averaging $1,540 per prescription, patients paid around $35 out of pocket per fill, according to the study.
